CORRECTION: An earlier version of this story said Health Canada had approved several generics for semaglutide. They have received several submissions for approval for ...

Get the Well Enough newsletter with Harry Bullmore for tips on living a healthier, happier and longer life Get the Well Enough email with Harry Bullmore The expiration of patents opens the door for ...

Albertans may see more and less-expensive varieties of Ozempic on the market soon, after a patent on the drug expired two weeks ago. Ozempic has made headlines in recent years as a popular weight-loss ...

British Columbians could soon have access to cheaper versions of injectable diabetes and obesity drugs. Health Canada is reviewing nine submissions for generic versions of semaglutide, a prescription ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

Adderall is a central nervous system stimulant that's prescribed to treat two conditions, attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. If you're ...

Abstract: Mobile Crowdsensing (MCS) has become a popular sensing paradigm, where a number of participants use their mobile devices to collectively share and extract information related to a certain ...

The decision enraged opponents of abortion, who have been pressuring the Trump administration to restrict access to abortion medication. By Pam Belluck The Food and Drug Administration has approved a ...

Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...

July 11 (Reuters) - Novartis (NOVN.S), opens new tab cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent ...

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection. Novo Nordisk will lose its patent ...